X-CELEPRINT LIMITED

AMBROSIA aims to provide the foundations for a multi-sensing future-proof Point of Care Unit for sepsis diagnosis offered by a CMOS compatible toolkit and enhanced by on-chip photonic neural network technology to provide an accurate and rapid diagnosis. AMBROSIA will be investing in the established ultra-small-footprint and elevated sensitivity of integrated plasmo-photonic sensors reinforced by the well-known on-chip slow-light effect and micro-transfer printed lasers and photodiodes on Si3N4, as well as the functional processing and classification portfolio of integrated photonic neural network engines, towards painting the landscape of the next-coming disruption in sensor evolution, tailoring them in System-in-Package prototype assemblies, with the sensors being cheap disposable pluggable modules that can rapidly and accurately diagnose sepsis at the bedside in clinical environments. AMBROSIA targets to demonstrate a Point of Care Unit incorporating: i) a switchable sensor area array, with each sensor area facilitating a pluggable, 8-channel label-free plasmo-photonic sensor for sepsis diagnosis with a sensitivity over 130.000nm/RIU and a Limit of Detection below 10-8 RIU for each interferometric sensor, ii) an embedded Si3N4 photonic neural network processing and classifying at the same time the data from at least 7 biomarkers with zero-power providing in the first minutes an accurate and rapid diagnosis for sepsis, iii) Micro-transfer printed lasers and photodetectors on chip that will drastically decrease costs of both the sensing and neural network modules, and render the sensor arrays disposable.

EC contribution:

EUR 333k

Start:

2023-01-01

End:

2026-12-31

Status:

SIGNED

Scheme:

HORIZON-RIA

Call:

HORIZON-CL4-2022-DIGITAL-EMERGING-01

View on CORDIS (DOI 10.3030/101093166)